Today marks an exciting new chapter as Catalyst Pharmaceuticals joins @AngeliniPharma as their newly formed Global Rare Disease Business Unit. By bringing together Catalyst's deep expertise in rare diseases with Angelini Pharma's global reach and capabilities, we are strengthening our shared dedication to advancing innovation and improving the lives of patients around the world. Our commitment remains the same: to serve patients, healthcare providers, caregivers, advocacy partners, the rare disease community, and our employees with the dedication and excellence they desire and have come to expect from Catalyst. We look forward to what's ahead as we continue building the future together. Learn more: angelinipharma.com/news-medi… #AngeliniPharma #BrainHealth #RareDisease

If you are on a Catalyst treatment and want help navigating your care journey, be a part of Catalyst Pathways. With different enrollment benefits like a Patient Access Liaison (PAL) and Care Coordinator to help you, and financial support, there are many reasons to join. Learn more about Catalyst Pathways: yourcatalystpathways.com/. #CatalystPathways #raredisease

Attending the Florida Cancer Specialists (FCS)'s Clinical Summit in Orlando? We'd love to connect. This event brings together physicians, advanced practice providers, researchers, and healthcare leaders for clinical education, collaboration, and discussions focused on advancing patient care. Visit us to learn more about Lambert-Eaton myasthenic syndrome (LEMS) and its association with small cell lung cancer (SCLC): cancerassociatedlems.com/. #oncology #cancer #SCLC #LEMS

Are there some things you don't know about Lambert-Eaton myasthenic syndrome (LEMS)? LEMS is considered a rare disease, and since some of its symptoms are similar to other diseases, it is frequently misdiagnosed. Learn more: catalystpharma.com/lems #LEMS #raredisease

Team Catalyst is at @JADPRO Live! Did you know that cases of Cancer-Associated Lambert-Eaton myasthenic syndrome (CA-LEMS) can go undiagnosed? Visit our booth #219 to learn more about the connection between small cell lung cancer (SCLC) and LEMS: cancerassociatedlems.com/. #JADPROLive #LEMS #SCLC #oncology

Greetings from @ChildNeuroSoc's Annual Meeting in Montreal! Team Catalyst is again proud to be part of a conference filled with cutting-edge research, engaging sessions, and opportunities to connect with the neuromuscular community. Stop by booth #407 to chat with us about Duchenne muscular dystrophy (DMD): catalystpharma.com/dmd. #ChildNeurologySociety #DMD #Duchenne

Catalyst offers a range of programs designed to help ensure patients can access the treatment they need. Learn more about our affordable, accessible treatment support through Catalyst Pathways: yourcatalystpathways.com/dmd…. #CatalystPathways #support #raredisease

Life isn't measured by what might happen tomorrow. It's measured by the moments we create today. Jeff “Riot,” Founder of Mile Monsters Inc., shares a simple message: your dreams and adventures don’t change. If there’s something you want to do, you can find your own path and timing to get there. For kids living with Duchenne muscular dystrophy (DMD), it’s about keeping your eyes on what’s ahead. Listen to #CatalystConvos: catalystpharma.com/catalyst-… #DMD #Duchenne #MileMonsters

Our Advocacy team is joining the conversation at the Black Autoimmune Disease Forum. Organized by the Myasthenia Gravis Holistic Society, the event highlights the importance of representation and holistic wellness in autoimmune health. We're grateful to be part of a space dedicated to listening, learning, and supporting efforts to amplify Black autoimmune voices: blackautoimmune.org/. Let us know if you're attending! #BlackAutoimmuneSummit #MG #PatientAdvocacy

At @ASBMR's Annual Meeting? We're here, at the the world's largest meeting in the bone, mineral, and musculoskeletal research field! Come learn about our work in Duchenne muscular dystrophy (DMD), a rare neuromuscular disease at booth #817: catalystpharma.com/dmd. #DMD #ASBMR2026 #Duchenne

We're live at @AANmember's Fall Conference! Explore our work in the rare neuromuscular disease space, specifically focusing on Lambert-Eaton myasthenic syndrome (LEMS) and Duchenne muscular dystrophy (DMD), and learn more about our ongoing efforts and how you can get involved: catalystpharma.com/. Come visit us at both of our booths, #508 & #708. See you there! #LEMS #DMD #neuromuscular #AANFC

The Catalyst team is proud to be attending @FLASCO_ORG's Congress 2026. We’re looking forward to joining oncology professionals from across the field as they exchange insights and work toward improving outcomes for patients. Come visit us to learn more about how Lambert-Eaton myasthenic syndrome (LEMS) is often linked to a small cell lung cancer (SCLC) diagnosis: cancerassociatedlems.com/. #oncology #SCLC #LEMS #FLASCO

Catalyst is returning to the @NotreDame's Brumm Patient Advocacy Summit! Last year, we had the privilege of exploring the role of the patient voice in drug development and hearing powerful stories from patients and caregivers. Our Executive Director of Patient Advocacy, Amy, will be on the Identifying Your Rare Disease Village panel, and we are excited to be back this year to learn from patients, caregivers, healthcare providers, advocates, and industry leaders as they share experiences and innovative ideas that continue to move the rare disease community forward: patientadvocacy.nd.edu/commu…. #PatientAdvocacy #Summit #NotreDame

We are pleased to share Catalyst’s 2025 Sustainability Report. We look forward to continuing our #sustainability work as part of @AngeliniPharma, with a shared commitment to creating lasting value for all our stakeholders. View our full #SustainabilityReport: catalystpharma.com/wp-conten…

Are you a young adult living with Duchenne and aged 18 or older? Or do you know someone who is? Consider applying for the Young Adults with Duchenne Patient Advisory Committee (YAD-PAC)! It's an opportunity to share your experiences, connect with others who understand the journey, and help ensure the voices of young adults in the Duchenne community are heard: rx4good.qualtrics.com/jfe/fo…. #Duchenne #DMD

On World Smile Day, we're celebrating our rare disease community. Check out these smiles: catalystpharma.com/. #WorldSmileDay #raredisease

At @IONOncologyGPO's 2026 Oncology Exchange Fall? Let’s start a conversation. We’re excited to connect with oncology professionals and industry leaders as they discuss the evolving landscape of cancer care and the advancements improving patient outcomes. Be sure to stop by and learn more about Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular disorder commonly associated with small cell lung cancer (SCLC): cancerassociatedlems.com/ #ExchangeFall2026 #SCLC #LEMS

Happy #InternationalPodcastDay! Looking for something meaningful to add to your listening queue? #CatalystConvos features conversations that matter to people impacted by rare diseases, including Lambert-Eaton myasthenic syndrome (#LEMS), Duchenne muscular dystrophy (#DMD), and epilepsy. Through personal stories from community members and insights from experts, each episode is designed to educate, inspire, and empower. Whether you're a patient, caregiver, advocate, or healthcare professional, there's something to learn from every conversation. Tune in, listen, and be part of the discussion: catalystpharma.com/catalyst-…. #podcast #raredisease

We’re on the ground at the 2026 @AANEMorg Annual Meeting! Connecting with the rare neuromuscular disease community is central to everything we do. Come meet our team and see how we’re working to support patients: catalystpharma.com/ #AANEM2026

Are you at the World Muscle Society (WMS)? Connect with the Catalyst team to see how we are committed to continuously raising awareness and providing support to the rare neuromuscular disease community: catalystpharma.com/ #WMS2026 #DMD

We were proud to join the global thoracic oncology community at @IASLC's WCLC where researchers, clinicians, and industry leaders come together to advance lung cancer care and innovation. Alongside meaningful collaboration and conversations, we highlighted an important connection: some patients who have a small cell lung cancer (SCLC) diagnosis may also have Cancer-Associated Lambert-Eaton Myasthenic Syndrome (CA-LEMS). Learn more: cancerassociatedlems.com/ #oncology #WCLC26